



IFW

THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No.: 40923-0079 US5 (18733-1302)

Applicant: Gary L. GRIFFITHS *et al.*

Confirmation No.: 6078

Appl. No.: 10/706,852

Group Art Unit: 1642

Filing Date: November 12, 2003

Examiner: To Be Assigned

Title: ANTI-CD74 IMMUNOCONJUGATES AND METHODS

**INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §1.56 and 37 CFR §1.97**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

To comply with Applicants' duty of disclosure pursuant to 37 C.F.R. §1.56 and §1.97, Applicants submit herewith on attached Form PTO/SB/08A, a listing of documents known to Applicants. A copy of each of the listed documents is being submitted to comply with the provisions of 37 C.F.R. §§1.97-1.99.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or is considered to be material to patentability as defined in 37 C.F.R. §1.56(b). Applicants do not waive any rights to take any action that would be appropriate to antedate or otherwise remove as a competent reference any document that is determined to be a *prima facie* prior art reference against the claims of the present application.


This Information Disclosure Statement is being filed in compliance with 37 CFR §1.97(b) prior to the mailing date of the first Office Action. Therefore, Applicants believe that

no fee is required at this time. However, the Commissioner is hereby authorized to charge any deficiency or to credit any overpayment to Deposit Account No. 08-1641.

Applicants respectfully request that the listed documents be considered by the Examiner and made of record in the present application and that an initialed copy of Form PTO/SB/08A be returned in accordance with M.P.E.P. §609.

Respectfully submitted,

Date: November 29, 2004

By: 
Paul M. Booth
Attorney for Applicant
Registration No. 40,244

HELLER EHRMAN WHITE &
MCAULIFFE LLP
1666 K Street, N.W., Suite 300
Washington, DC 20006-1228
Telephone: (202) 912-2000
Facsimile: (202) 912-2020
Customer No. 26633



PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/706,852
				Filing Date	November 12, 2003
				First Named Inventor	Gary L. GRIFFITHS <i>et al.</i>
				Art Unit	1642
Sheet	I	of	10	Examiner Name	To Be Assigned
				Attorney Docket Number	40923-0079 US5 (18733-1302)

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ²			
	1.	US-4,036,945	07-19-1977	Haber	
	2.	US-4,046,722	09-06-1977	Rowland	
	3.	US-4,331,647	05-25-1982	Goldenberg	
	4.	US-4,699,784	10-13-1987	Shih <i>et al.</i>	
	5.	US-4,704,692	11-03-1987	Ladner	
	6.	US-4,824,659	04-25-1989	Hawthorne	
	7.	US-4,916,213	04-10-1990	Scannon <i>et al.</i>	
	8.	US-4,918,163	04-17-1990	Young <i>et al.</i>	
	9.	US-4,925,922	05-15-1990	Byers <i>et al.</i>	
	10.	US-4,932,412	06-12-1990	Goldenberg	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				
	1.	EP 0 510 949 A2	10-28-1992	Pouletty		
	2.	EP 0 332 865 A2	09-20-1989	Meyer <i>et al.</i>		
	3.	WO 91/13974	09-19-1991	Pesando		
	4.	WO 94/27638	12-08-1994	Tedder <i>et al.</i>		
	5.	WO 95/09917	04-13-1995	Morrison <i>et al.</i>		
	6.	WO 96/04925	02-22-1996	Leung <i>et al.</i>		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*Examiner: Initial reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	10/706,852
				Filing Date	November 12, 2003
				First Named Inventor	Gary L. GRIFFITHS <i>et al.</i>
				Art Unit	1642
				Examiner Name	To Be Assigned
Sheet	2	of	10	Attorney Docket Number	40923-0079 US5 (18733-1302)

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ²	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	11.	US-4,946,778	08-07-1990	Ladner <i>et al.</i>	
	12.	US-5,057,313	10-15-1991	Shih <i>et al.</i>	
	13.	US-5,134,075	07-28-1992	Hellstrom <i>et al.</i>	
	14.	US-5,171,665	12-15-1992	Hellstrom <i>et al.</i>	
	15.	US-5,196,337	03-23-1993	Ochi <i>et al.</i>	
	16.	US-5,204,095	04-20-1993	Goodall <i>et al.</i>	
	17.	US-5,229,275	07-20-1993	Goroff	
	18.	US-5,443,953	08-22-1995	Hansen <i>et al.</i>	
	19.	US-5,484,892	01-16-1996	Tedder <i>et al.</i>	
	20.	US-5,525,338	06-11-1996	Goldenberg	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ Number ⁴ Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
	7.	WO 98/42378	10-01-1998	Goldenberg		
	8.	WO 98/50435	11-12-1998	Rybak <i>et al.</i>		
	9.	WO 99/02567	01-21-1999	Ghetie <i>et al.</i>		
	10.	WO 99/54440	10-28-1999	Kufer <i>et al.</i>		
	11.	WO 00/29584 A1	05-25-2000	Chen <i>et al.</i>		
	12.	WO 00/67795	11-16-2000	Goldenberg <i>et al.</i>		
	13.	WO 00/74718 A1	12-14-2000	Goldenberg <i>et al.</i>		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*Examiner: Initial reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	10/706,852
				Filing Date	November 12, 2003
				First Named Inventor	Gary L. GRIFFITHS <i>et al.</i>
				Art Unit	1642
				Examiner Name	To Be Assigned
Sheet	3	of	10	Attorney Docket Number	40923-0079 US5 (18733-1302)

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ²	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	21.	US-5,565,215	10-15-1996	Gref <i>et al.</i>	
	22.	US-5,567,610	10-22-1996	Borrebaeck <i>et al.</i>	
	23.	US-5,593,676	01-14-1997	Bhat <i>et al.</i>	
	24.	US-5,620,708	04-15-1997	Amkraut <i>et al.</i>	
	25.	US-5,633,425	05-27-1997	Lonberg <i>et al.</i>	
	26.	US-5,686,072	11-11-1997	Uhr <i>et al.</i>	
	27.	US-5,702,727	12-30-1997	Amkraut <i>et al.</i>	
	28.	US-5,716,595	02-10-1998	Goldenberg	
	29.	US-5,736,119	04-07-1998	Goldenberg <i>et al.</i>	
	30.	US-5,776,456	07-07-1998	Anderson <i>et al.</i>	
	31.	US-5,789,554	08-04-1998	Leung <i>et al.</i>	
	32.	US-5,795,967	08-18-1998	Aggarwal <i>et al.</i>	
	33.	US-5,798,554	08-25-1998	Grimaldi <i>et al.</i>	
	34.	US-5,874,540	02-23-1999	Hansen <i>et al.</i>	
	35.	US-5,922,302	07-13-1999	Goldenberg <i>et al.</i>	
	36.	US-6,051,228	04-18-2000	Aruffo <i>et al.</i>	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ Number ⁴ Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*Examiner: Initial reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	10/706,852
				Filing Date	November 12, 2003
				First Named Inventor	Gary L. GRIFFITHS <i>et al.</i>
				Art Unit	1642
				Examiner Name	To Be Assigned
Sheet	4	of	10	Attorney Docket Number	40923-0079 US5 (18733-1302)

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ²	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	37.	US-6,077,499	06-20-2000	Griffiths <i>et al.</i>	
	38.	US-6,096,289	08-01-2000	Goldenberg	
	39.	US-6,165,440	12-26-2000	Esenaliev	
	40.	US-6,183,744	02-06-2001	Goldenberg	
	41.	US-6,187,287	02-13-2001	Leung <i>et al.</i>	
	42.	US-6,254,868	07-03-2001	Leung <i>et al.</i>	
	43.	US-6,306,393	10-23-2001	Goldenberg	
	44.	US-6,331,175	12-18-2001	Goldenberg	
	45.	US-6,379,698	04-30-2002	Leamon	
	46.	US-6,387,350	05-14-2002	Goldenberg	
	47.	US-6,395,276	05-28-2002	Rybak <i>et al.</i>	
	48.	US-6,530,944	03-11-2003	West <i>et al.</i>	
	49.	US-6,558,648	05-06-2003	Griffiths <i>et al.</i>	
	50.	US-6,562,318	05-13-2003	Filler	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*Examiner: Initial reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	10/706,852
				Filing Date	November 12, 2003
				First Named Inventor	Gary L. GRIFFITHS <i>et al.</i>
				Art Unit	1642
				Examiner Name	To Be Assigned
Sheet	5	of	10	Attorney Docket Number	40923-0079 US5 (18733-1302)

NON-PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	1.	Ansel <i>et al.</i> , <i>Pharmaceutical Dosage Forms and Drug Delivery Systems</i> , 5th Ed., Lea & Febiger (1990).	
	2.	Bally, <i>et al.</i> , <i>J. Liposome Res.</i> , 8(3):299 (1998).	
	3.	Bendas, <i>Biodrugs</i> , 15(4):215 (2001).	
	4.	Bendig <i>et al.</i> , <i>Methods: A Companion to Methods in Enzymology</i> , 8:83 (1995).	
	5.	Bird <i>et al.</i> , <i>TIBTECH</i> , 9:132 (1991).	
	6.	Bom <i>et al.</i> , <i>J. Controlled Release</i> , 74:325 (2001).	
	7.	Carter <i>et al.</i> , <i>Proc. Natl. Acad. Sci. USA</i> , 89:4285 (1992).	
	8.	Cochlovius <i>et al.</i> , <i>Cancer Research</i> , 60: 4336 (2000).	
	9.	Coligan <i>et al.</i> (eds.), <i>Current Protocols in Immunology</i> , Vol. 1, pp. 2.5.1-2.6.7; pp. 2.7.1-2.7.12; 2.8.1-2.8.10; 2.9.1-2.9.3, and 2.10-2.10.4, John Wiley & Sons (1991).	
	10.	Coloma <i>et al.</i> , <i>Nature Biotech</i> , 15:159 (1997).	
	11.	Constantinides <i>et al.</i> , <i>Pharm. Res.</i> , 17(2):175 (2000).	
	12.	Courtenay-Luck, "Genetic Manipulation of Monoclonal Antibodies", <i>Monoclonal Antibodies: Production, Engineering, and Clinical Application</i> , pp. 166-179, Ritter <i>et al.</i> , eds., Cambridge University Press (1995).	
	13.	Edelman <i>et al.</i> , <i>Methods in Enzymology</i> , Vol. 1, p. 422, Academic Press (1955).	
	14.	FitzGerald <i>et al.</i> , <i>Protein Eng.</i> , 10(10):1221 (1997).	
	15.	Flavell <i>et al.</i> , <i>Cancer Res.</i> , 57:4824 (1997).	
	16.	Freedman <i>et al.</i> , "Non-Hodgkin's Lymphomas," in <i>Cancer Medicine</i> , Vol. 2, 3rd Edition, pp. 2028-2068, Holland <i>et al.</i> (eds.), Lea & Febiger (1993).	
	17.	French <i>et al.</i> , <i>Leukemia Res.</i> , 20(7):607 (July 1996).	
	18.	Gennaro, <i>Remington's Pharmaceutical Sciences</i> , 18th Ed., Mack Publishing Co. (1990).	
	19.	Gennaro, <i>Remington's Pharmaceutical Sciences</i> , 19th Ed., Vol. I and II, Mack Publishing Co. (1995).	
	20.	Ghetie <i>et al.</i> , <i>Cancer Res.</i> , 48:2610 (1988).	

Examiner Signature	Date Considered
--------------------	-----------------

*Examiner: Initial reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application. ¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	10/706,852
				Filing Date	November 12, 2003
				First Named Inventor	Gary L. GRIFFITHS <i>et al.</i>
				Art Unit	1642
				Examiner Name	To Be Assigned
Sheet	6	of	10	Attorney Docket Number	40923-0079 US\$ (18733-1302)

NON-PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	21.	Goldenberg, <i>Scientific American, Science & Medicine</i> , 1:64 (1994).	
	22.	Goldenberg, <i>Semin. Nucl. Med.</i> , 19(4):332 (1989).	
	23.	Goldenberg, <i>CA-A Cancer J. for Clinicians</i> , 44(1):43 (1994).	
	24.	Goodman and Gilman's <i>The Pharmacological Basis of Therapeutics</i> , 7th Ed., MacMillan Publishing Co. (1985).	
	25.	Green <i>et al.</i> , <i>Nature Genet.</i> , 7:13 (1994).	
	26.	Hansen <i>et al.</i> , <i>Biochem. J.</i> , 320:293 (1996).	
	27.	Harlow & Lane (eds), <i>Antibodies, A Laboratory Manual</i> , Cold Spring Harbor Laboratory, NY (1988).	
	28.	Hasan <i>et al.</i> , <i>Prog. Clin. Biol. Res.</i> , 288:471 (1989).	
	29.	Hekman <i>et al.</i> , <i>Cancer Immunol. Immunother.</i> , 32:364 (1991).	
	30.	Hess <i>et al.</i> , <i>Blood</i> , 89(6): 2203 (1997).	
	31.	Huse <i>et al.</i> , <i>Science</i> , 246:1275 (1989).	
	32.	Johnson <i>et al.</i> , <i>Current Opin. Struct. Biol.</i> , 3:564 (1993).	
	33.	Jones <i>et al.</i> , <i>Nature</i> , 321:522 (1986).	
	34.	Jori <i>et al.</i> , <i>Photodynamic Therapy of Tumors and Other Diseases</i> , Libreria Progetto (1985).	
	35.	Juweid <i>et al.</i> , <i>Nuc. Med. Comm.</i> , 18:142 (1997).	
	36.	Juweid <i>et al.</i> , <i>Cancer Res. (suppl.)</i> , 55:5899s (1995).	
	37.	Kaminski <i>et al.</i> , <i>New Eng. J. of Med.</i> , 329(7):459 (1993).	
	38.	Kiesel <i>et al.</i> , <i>Leukemia Res.</i> , 11(12):1119 (1987).	
	39.	Kirpotin, <i>et al.</i> , <i>Biochemistry</i> , 36:66 (1997).	
	40.	Köhler <i>et al.</i> , <i>Nature</i> , 256:495 (1975).	
	41.	Koning <i>et al.</i> , <i>Biochim. Biophys. Acta</i> , 1420:153 (1999).	
	42.	Kreitman <i>et al.</i> , <i>Cancer Research</i> , 53:819 (1993).	
	43.	Larrick <i>et al.</i> , <i>Methods: A Companion to Methods in Enzymology</i> , 2(2):106 (1991).	
	44.	Leonard <i>et al.</i> , <i>Blood</i> , 94(10), suppl. 1, part 1, abstract #404 (1999).	
	45.	Leung <i>et al.</i> , <i>Hybridoma</i> , 13:469 (1994).	

Examiner Signature	Date Considered
--------------------	-----------------

*Examiner: Initial reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application. ¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	10/706,852
				Filing Date	November 12, 2003
				First Named Inventor	Gary L. GRIFFITHS <i>et al.</i>
				Art Unit	1642
				Examiner Name	To Be Assigned
Sheet	7	of	10	Attorney Docket Number	40923-0079 US5 (18733-1302)

NON-PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	46.	Leung <i>et al.</i> , <i>J. Immunol.</i> , 154:5919 (1995).	
	47.	Leung <i>et al.</i> , <i>Mol. Immunol.</i> , 32(17/18):1413 (1995).	
	48.	Levine <i>et al.</i> , <i>Neurology</i> , 52(8):1701 (1999).	
	49.	Li <i>et al.</i> , <i>Cellular Immunol.</i> , 118:85 (1989).	
	50.	Lonberg <i>et al.</i> , <i>Nature</i> , 368:856 (1994).	
	51.	Longo, <i>Curr. Opin. Oncol.</i> , 8:353 (1996).	
	52.	Lopes de Menezes <i>et al.</i> , <i>Cancer Res.</i> , 58:3320 (1998).	
	53.	Lopes de Menezes, <i>et al.</i> , <i>J. Liposome Res.</i> , 9(2):199 (1999).	
	54.	Lundberg, <i>J. Pharm. Sci.</i> , 83(1):72 (1994).	
	55.	Lundberg, <i>Int. J. Pharm.</i> , 109:73 (1994).	
	56.	Lundberg <i>et al.</i> , <i>Int. J. Pharm.</i> , 134:119 (1996).	
	57.	Lundberg, <i>J. Pharm. Pharmacol.</i> , 49:16 (1997).	
	58.	Lundberg, <i>Anti-Cancer Drug Design</i> , 13:453 (1998).	
	59.	Lundberg <i>et al.</i> , <i>J. Pharm. Pharmacol.</i> , 51:1099 (1999).	
	60.	Lundberg <i>et al.</i> , <i>Int. J. Pharm.</i> , 205:101 (2000).	
	61.	Mack <i>et al.</i> , <i>Proc. Natl. Acad. Sci. USA</i> , 92:7021 (1995).	
	62.	Maloney <i>et al.</i> , <i>Blood</i> , 84(8):2457 (1994).	
	63.	Maranhão <i>et al.</i> , <i>Cancer. Chemother. Pharmacol.</i> , 49:487 (2002).	
	64.	McCafferty <i>et al.</i> , <i>Nature</i> , 348:552 (1990).	
	65.	Mendez <i>et al.</i> , <i>Nature Genetics</i> , 15:146 (1997).	
	66.	The Merck Manual of Diagnosis & Therapy, pp. 1474-1476, Chap. 180, 17th Ed., Beers <i>et al.</i> , Merck Research Labs, Whitehouse Station, NJ (1999).	
	67.	Mew <i>et al.</i> , <i>J. Immunol.</i> , 130(3):1473 (1983).	
	68.	Mew <i>et al.</i> , <i>Cancer Res.</i> , 45:4380 (1985).	
	69.	Moase <i>et al.</i> , <i>Biochim. Biophys. Acta</i> , 1510:43 (2001).	
	70.	Möller <i>et al.</i> , <i>J. Biol. Regul. Homeost. Agents</i> , 14(4):299 (2000).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*Examiner: Initial reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application. ¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	10/706,852
				Filing Date	November 12, 2003
				First Named Inventor	Gary L. GRIFFITHS <i>et al.</i>
				Art Unit	1642
				Examiner Name	To Be Assigned
Sheet	8	of	10	Attorney Docket Number	40923-0079 US5 (18733-1302)

NON-PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	71.	Mosmann, <i>J. Immunol. Meth.</i> , 65:55 (1983).	
	72.	Nisonoff <i>et al.</i> , <i>Arch. Biochem. Biophys.</i> , 89:230 (1960).	
	73.	Ochakovskaya <i>et al.</i> , <i>Clin. Cancer Res.</i> , 7(6):1505 (2001).	
	74.	Orlandi <i>et al.</i> , <i>Proc. Natl. Acad. Sci. USA</i> , 86:3833 (1989).	
	75.	Oseroff <i>et al.</i> , <i>Proc. Natl. Acad. Sci. USA</i> , 83:8744 (1986).	
	76.	Oseroff <i>et al.</i> , <i>Photochem. Photobiol.</i> , 46:83 (1987).	
	77.	Pastan <i>et al.</i> , <i>Cell</i> , 47:641 (1986).	
	78.	Patti <i>et al.</i> , <i>Eur. J. Haematol.</i> , 51:18 (1993).	
	79.	Pawlak-Byczkowska <i>et al.</i> , <i>Cancer Res.</i> , 49:4568 (1989).	
	80.	Pèlegri <i>et al.</i> , <i>Cancer</i> , 67:2529 (1991).	
	81.	Perkins <i>et al.</i> , <i>Int. J. Pharm.</i> 200:27 (2000).	
	82.	Pirker <i>et al.</i> , <i>J. Clin. Invest.</i> , 76:1261 (1985).	
	83.	Porter, <i>Biochem. J.</i> , 73:119 (1959).	
	84.	Press <i>et al.</i> , <i>N. Eng. J. Med.</i> , 329(17):1219 (1993).	
	85.	Press <i>et al.</i> , <i>The Lancet</i> , 346:336 (1995).	
	86.	Press, <i>Cancer Journal from Scientific American</i> , 4:S19 (1998).	
	87.	Price, "Production and Characterization of Synthetic Peptide-Derived Antibodies", <i>Monoclonal Antibodies: Production, Engineering, and Clinical Application</i> , Ritter <i>et al.</i> , eds., pp. 60-84, Cambridge University Press (1995).	
	88.	Protheroe <i>et al.</i> , <i>Rheumatology</i> , 38:1150 (1999).	
	89.	Qu <i>et al.</i> , <i>J. Immunol. Methods</i> , 213(2):131 (1998).	
	90.	Qu <i>et al.</i> , "Internalization and Cytotoxic Effects of a Humanized Anti-CD74 Antibody, LL1", <i>Proc. Ann. Meeting American Assoc. Cancer Res.</i> , New York, NY, Vol. 43:255, XP001152818 (2002).	
	91.	Raag <i>et al.</i> , <i>FASEB</i> , 9:73 (1995).	

Examiner Signature	Date Considered
--------------------	-----------------

*Examiner: Initial reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application. ¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	10/706,852
				Filing Date	November 12, 2003
				First Named Inventor	Gary L. GRIFFITHS <i>et al.</i>
				Art Unit	1642
				Examiner Name	To Be Assigned
Sheet	9	of	10	Attorney Docket Number	40923-0079 US5 (18733-1302)

NON-PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	92.	Renner <i>et al.</i> , <i>Leukemia</i> , 11, supp. 2:S55 (1997).	
	93.	Riechmann <i>et al.</i> , <i>Nature</i> , 332:323 (1988).	
	94.	Rowan <i>et al.</i> , <i>Immunology</i> , 95(3):427 (1998).	
	95.	Ryser <i>et al.</i> , <i>Proc. Natl. Acad. Sci. USA</i> , 75(8):3867 (1978).	
	96.	Saltzman <i>et al.</i> , <i>Biophys. J.</i> , 55:163 (1989).	
	97.	Sandhu, <i>Crit. Rev. Biotech.</i> , 12(5/6):437 (1992).	
	98.	Sherwood <i>et al.</i> , <i>Bio/Technology</i> , 10:1446 (1992).	
	99.	Shih <i>et al.</i> , <i>Int. J. Cancer</i> , 41:832 (1988).	
	100.	Shih <i>et al.</i> , <i>Int. J. Cancer</i> , 46:1101 (1990).	
	101.	Shih <i>et al.</i> , <i>Int. J. Cancer</i> , 56:538 (1994).	
	102.	Shih <i>et al.</i> , <i>Cancer Immunol. Immunother.</i> , 49:208 (2000).	
	103.	Singer <i>et al.</i> , <i>J. Immun.</i> , 150:2844 (1993).	
	104.	Stein <i>et al.</i> , <i>Cancer Immunol. Immunother.</i> , 37(5):293 (1993).	
	105.	Straubinger, <i>et al.</i> , <i>Biochemistry</i> , 29:4929 (1990).	
	106.	Tatsuta <i>et al.</i> , <i>Lasers Surg. Med.</i> , 9:422 (1989).	
	107.	Taylor <i>et al.</i> , <i>Int. Immun.</i> , 6(4):579 (1994).	
	108.	Tempest <i>et al.</i> , <i>Biotechnology</i> , 9:266 (1991).	
	109.	Theocharis <i>et al.</i> , <i>Clin. Immunol. Immunopathol.</i> , 74(2):135 (1995).	
	110.	Thorpe, <i>TIBTECH</i> , 11:42 (1993).	
	111.	Torchilin, <i>et al.</i> , <i>Proc. Natl. Acad. Sci. USA</i> , 100(10): 6039 (2003).	
	112.	Upeslakis <i>et al.</i> , "Modification of Antibodies by Chemical Methods", <i>Monoclonal Antibodies: Principles and Applications</i> , pp. 187-230, Birch <i>et al.</i> (eds.), Wiley-Liss (1995).	
	113.	Van den Bergh, <i>Chem. Britain</i> , 22:430 (1986).	
	114.	Vaughan <i>et al.</i> , <i>Nat. Biotechnol.</i> , 14:309 (1996).	
	115.	Verhoeven <i>et al.</i> , <i>Science</i> , 239:1534 (1988).	

Examiner Signature	Date Considered
--------------------	-----------------

*Examiner: Initial reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application. ¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	10/706,852
				Filing Date	November 12, 2003
				First Named Inventor	Gary L. GRIFFITHS <i>et al.</i>
				Art Unit	1642
				Examiner Name	To Be Assigned
Sheet	10	of	10	Attorney Docket Number	40923-0079 US5 (18733-1302)

NON-PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	116.	Vuist <i>et al.</i> , <i>Cancer Res.</i> , 49:3783 (1989).	
	117.	Ward <i>et al.</i> , "Genetic Manipulation and Expression of Antibodies", <i>Monoclonal Antibodies: Principles and Applications</i> , pp. 137-185, Birch <i>et al.</i> (eds.), Wiley-Liss, Inc. (1995).	
	118.	West <i>et al.</i> , <i>Curr. Opin. Biotech.</i> , 11:215 (2000).	
	119.	Wong, <i>Chemistry of Protein Conjugation and Cross-Linking</i> , CRC Press (1991).	
	120.	Wrobel <i>et al.</i> , <i>Biochimica et Biophysica Acta</i> , 1235:296 (1995).	
	121.	Xu <i>et al.</i> , <i>Mol. Cancer. Ther.</i> , 1:337 (2002).	
	122.	Yu <i>et al.</i> , <i>Int. J. Cancer</i> , 56:244 (1994).	
	123.	U.S. Patent Application Publication No. 2002/0071807 A1.	
	124.	U.S. Patent Application Publication No. 2003/0082154.	
	125.	U.S. Patent Application Publication No. 2003/0124058 A1.	
	126.	Griffiths <i>et al.</i> , "Cure of SCID Mice Bearing Human B-Lymphoma Xenografts by an Anti-CD74 Antibody-Anthracycline Drug Conjugate" (manuscript).	
	127.	Lundberg <i>et al.</i> , "Cellular Association and Cytotoxicity of Anti-CD74-Targeted Lipid Drug-Carriers in B Lymphoma Cells" (manuscript).	
	128.		
	129.		
	130.		
	131.		
	132.		
	133.		
	134.		
	135.		
	136.		
	137.		
	138.		
	139.		

Examiner Signature	Date Considered
--------------------	-----------------

*Examiner: Initial reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application. ¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.